Shanghai Medicilon Inc.

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

  Recently, Shanghai Medicilon Inc. (hereinafter referred to as "Medicilon") appointed Dr. Rui Zhang as Senior Vice President of Pharmaceutical Research. After this appointment, Dr. Zhang will further promote Medicilon to enter the CDMO field, help Medicilon to establish a large-scale production base in line with GMP standards through strategic cooperation, self-construction or merger and acquisition, further improve the crystal research service platform, strengthen the construction of technical platform in the field of small nucleic acid drugs and polypeptide drug preparations, and help Medicilon achieve "CRO+CDMO" two-wheel drive. At the same time, Dr. Zhang will also further promote the business development of Medicilon and help Medicilon to research and develop new drugs. Dr. Rui Zhang, Ph.D., University of Victoria, Postdoc at the School of Pharmacy, University of Manitoba, has been deeply involved in the field of drug research and development for 15 years. He

  The MAH system has brought unprecedented opportunities and challenges to the Chinese pharmaceutical industry. Combined with the current development of the world's biopharmaceutical industry, the article will take you to understand the development pattern and current situation of the pharmaceutical CDMO industry, and understand the background of the CDMO industry development driven by policies and dividends. 01      Introduction to CDMO Industry Services The  CDMO (Contract Development Manufacture Organization) business model  includes the entire supply chain system from preclinical research, clinical trials to commercial production, including R&D, procurement, and production. It provides innovative process R&D and large-scale production services for pharmaceutical companies. Technology output with higher added value replaces pure capacity output. 02     Global CDMO Market Status, Scale 01   The global CDMO market size is nearly 100 billion US dollars In 2019, the global C

  In recent years, the global   CDMO  industry has maintained steady growth. In terms of revenue, Switzerland's   Lonza  ranks first, with sales of 5.4 billion Swiss francs in 2021, a year-on-year increase of 20%. Followed by are WuXi AppTec and WuXi Biologics, the total revenue was US$5.214 billion, a year-on-year increase of 49.83%, with nearly 45,000 total employees. There are 9 companies with revenue of more than 1 billion US dollars. Two companies wihch from China and South Korea are on the list. The rest are European and American companies, and there is only one company  Catalent  in the United States. From the perspective of revenue growth, WuXi has grown by 50% year-on-year last year, far exceeding other companies. Catalent's  revenue in last year was $3.998 billion, a year-on-year increase of 29%, ranking third. In March 2013, Catalent established the 8th clinical supply center in the world and the 1st clinical supply center in China, and named its Chinese company afte

  Lonza ranks first, and China's WuXi department (WuXi AppTec + WuXi Biologics) has ranked the second position in the world. Among the top 10, two Asian companies and European companies occupy the majority. 2021 Global CDMO Ranking Top 10 Rank Name Country Revenue(billions of dollars) growth rate(%) 1 Lonza Switzerland 4.810 12.5% 2 Wuxi China 3.389 31.78% 3 Catalent USA 3.094 22.9% 4 FAREVA SA France 2.137 - 5 Recipharm AB Sweden 1.303 30% 6 Samsung Bio Korea 1.034 14.5% 7 Delpharm France 0.945 - 8 Siegfried Sweden 0.913 1.40% 9 Boehringer Ingelheim Germany 0.905 5.6% 10 Aenova Group Germany 0.857 0.55% In terms of growth rate, WuXi ranks first. In terms of revenue scale, there is still a gap of nearly 1.5 billion US dollars between WuXi and Lonza. Global CDMO Enterprise Ranking There are some non-listed companies abroad whose financial data are not regularly disclosed, but their strength cannot be ignored. There are not many CDMO heads in China, and most of them have a revenue of

  On September 7, 2022, the opening ceremony of Medicilon (Hangzhou) Inc., a subsidiary of Shanghai Medicilon Inc., was held in Hangzhou. Medicilon (Hangzhou) will build as a CRO research center.  The nearly 8,000-square-meter R&D laboratory will focus on the biopharmaceuticals and AI pharmaceuticals, such as chemical drug synthesis research, compound synthesis, compound activity screening and other services.  This could accelerate the industrialization of research results.   About   Medicilon Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. We provide one-stop customized R&D solutions ranging from precise drug targeting to IND filing assistance. Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.   Medicilon Medicinal Che

  On September 21, 2022, Medicilon (Baoshan) Inc's, a subsidiary of Shanghai Medicilon Inc, groundbreaking ceremony was held in North Shanghai Parmaceutical Industrial Park.  This is another grand event following the opening of Medicilon (Hangzhou) on September 7. Medicilon (Baoshan) is located at the intersection of Panjing Road and Yueluo Road in Baoshan District, Shanghai.  The total investment of the project is RMB 1.57 billion, covering an area of 270,000 square meter, with a total construction area of over 150,000 square meters.  After the construction, Medicilon (Baoshan) will combine the most advanced technology and cutting-edge research fields of global drug research and development to establish a complete one-stop drug research and development platform with the ability to lead the new drug research and innovation, to establish different technology platform and to explore and form a higher level of scientific support for drug development and laboratory development pillars